INV 407
Alternative Names: INV-407Latest Information Update: 16 Oct 2023
Price :
$50 *
At a glance
- Originator INVENT Pharmaceuticals
- Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Anxiety disorders; Attention-deficit hyperactivity disorder; Major depressive disorder
Most Recent Events
- 16 Oct 2023 Investigation in Anxiety disorders in USA (PO) (Invent Pharmaceutical website, October 2023)
- 16 Oct 2023 Investigation in Major depressive disorder in USA (PO) (Invent Pharmaceutical website, October 2023)
- 31 Jul 2023 Invent Pharmaceuticals has patent protection for small molecules prior July 2023 (Invent Pharmaceuticals website, July 2023)